全体要約
プロセスセグメントでは、ヒット・ツー・リード特定が最も大きなシェアを占めています。欧州は北米に次ぐドラッグディスカバリーサービス市場の地域であり、新規化学物質や生物分子の開発とR&D活動の増加が成長を支えています。主要な企業には、アメリカのラボラトリーコーポレーションやサーモフィッシャーサイエンティフィックが含まれています。
関連する質問
41.3 billion USD（2028年）
14.9%（2023年から2028年）
Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., Charles River Laboratories International, Inc., WuXi AppTec, Eurofins Scientific SE, Evotec SE, Syngene International Limited, Curia Global Inc., Dr. Reddy Laboratories Ltd. (Aurigene Discovery Technologies), Pharmaron Beijing Co., Ltd., Piramal Enterprises Limited
製薬・バイオテクノロジー分野の研究開発費用の増加, 薬剤の研究開発パイプラインの増加とアウトソーシングへの依存度の高まり, 希少疾患およびオーファンドラッグに関する研究のための取り組み
概要
腫瘍学は治療領域セグメントで最大のシェアを占めると予測されています。
治療領域に基づいて、オンコロジーセグメントは最も大きな市場シェアを持っています。オンコロジー用の薬剤の開発リストは、臨床試験の増加と製薬会社のオンコロジーに基づく薬剤への研究開発支出の増加に伴い、年々増加しています。世界中でがんの発生率は急速に増加しています。GLOBOCANによると、新たな症例数は2020年の1930万から2040年までに2890万に達する見込みで、2020年から2040年までの年平均成長率は約2%です。このため、企業はがんに対する新しい薬の開発にますます注力しており、これがこの治療セグメントの成長を促進すると予想されています。
ヒット・トゥ・リード識別セグメントは、薬物探索サービス市場におけるプロセスセグメントの中で最大のシェアを占めました。
プロセスに基づいて、医薬品発見サービス市場は大きくターゲット選定、ターゲット検証、ヒットからリードの特定、リード最適化、および候補検証に分類されます。ヒットからリードの特定セグメントは、2022年に医薬品発見サービス市場の最大のシェアを占めました。医薬品発見プロセスにおける重要な役割のため、ヒットからリードの特定は最大の収益を生み出すプロセスであり、現在、多くの医薬品発見企業が特にこれらのサービスを製薬会社に提供。
ヨーロッパは薬物発見サービス市場で二番目に大きな地域です。
医薬品開発サービス市場は、北米、ヨーロッパ、アジア太平洋、ラテンアメリカ（LATAM）、中東およびアフリカ（MEA）にセグメント化されています。北米に次いで、ヨーロッパは世界で2番目に大きな地域の製薬市場です。研究主導の製薬産業は、進化するグローバル経済において将来の競争力を確保する上で重要な役割を果たすことができます（出典：EFPIA）。新しい化学および生物学的分子の開発と、研究開発（R&D）活動の増加が、ヨーロッパにおける医薬品開発サービス市場の成長を促進します。
このレポートで実施された主なインタビューは、次のように分類できます：
• 回答者別：供給側70％、需要側30％
• 職位別: マネージャー - 45%、CXOおよびディレクター職 - 30%、エグゼクティブ - 25%
地域別：北米 -20%、ヨーロッパ -10%、アジア太平洋 -55%、ラテンアメリカ -10%、中東・アフリカ -5%
医薬品発見サービス市場の著名なプレーヤーは、アメリカのラボラトリーコーポレーションオブアメリカホールディングス、アメリカのサーモフィッシャーサイエンティフィック、アメリカのチャールズリバーラボラトリーズインターナショナル、 中国のウーシーアプテック、ドイツのユーロフィン、ドイツのエボテック、インドのシンジェーンインターナショナル、アメリカのキュリアグローバル、インドのドクターレディーラボラトリーズ（アウリゲンディスカバリーテクノロジーズ）、中国のファーマロン北京、インドのピラマルエンタープライズです。
調査範囲：
この報告書は、ドラッグディスカバリー市場の詳細な概要を提供します。市場の規模と将来の成長可能性を、製品、アプリケーション、エンドユーザー、地域などの異なるセグメントで推定することを目的としています。また、主要な市場プレイヤーの競争分析、企業プロフィール、最近の動向、主要な市場戦略も含まれています。
報告書購入の主な利点：
この報告書は、市場のリーダーや新規参入者に対して、全体の医薬品発見市場およびそのサブセグメントの収益数値の最も近い推定値を提供することで支援します。また、利害関係者が競争環境をよりよく理解し、自身のビジネスを適切に位置づけ、市場進出戦略を立てるための洞察を得るのにも役立ちます。この報告書は、利害関係者が市場の動向を理解し、主要な市場ドライバー、制約、課題、トレンド、機会に関する情報を提供します。
報告書は以下のポイントについての洞察を提供します：
• 主要な推進要因の分析（製薬・バイオテクノロジー部門の研究開発支出の増加、薬剤の研究開発パイプラインの増加およびアウトソーシングへの依存の高まり、希少疾患およびオーファンドラッグに関する研究への取り組み、社内での薬剤開発の高コスト）、制約（薬剤発見および動物使用に関する厳格な規制）、機会（技術革新および新しい薬剤発見技術の進展、最終ユーザー間での専門的テストサービスへの需要の高まり、主要なバイオ医薬品の特許切れ、および新興市場における高い成長可能性）、および課題（熟練した人材の不足）が、薬剤発見サービス市場の成長に影響を与えています。
• サービス開発/イノベーション: 新たに発表されたサービスに関する詳細な洞察と、薬剤発見市場の技術的評価です。
市場開発: 有望な市場に関する包括的な情報 – この報告書は、さまざまな地域での医薬品発見サービス市場を分析しています。
市場の多様化：新しいサービス、未開拓の地域、最近の発展、および医薬品発見サービス市場への投資に関する詳細な情報です。
• 競争評価：米国のラボラトリー・コーポレーション・オブ・アメリカ・ホールディングス、米国のサーモフィッシャーサイエンティフィック株式会社、米国のチャールズリバージャボラトリーズインターナショナル、インク、中国のウーシーアプテックなどの主要プレーヤーの市場シェア、成長戦略、サービス提供の詳細な評価を行っています。このレポートは、ステークホルダーが創薬サービス市場の動向を理解し、主要な市場ドライバー、制約、課題、機会に関する情報を提供します。
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 イントロダクション 43
1.1 調査の目的 43
1.2 市場の定義 43
1.2.1 包含・除外事項 43
1.3 市場範囲 44
1.3.1 対象市場 44
1.4 対象年 44
1.5 通貨 45
1.6 制約 45
1.7 ステークホルダー 45
1.8 変化のサマリー 46
1.8.1 リセッション時のインパクト 46
2 調査手法 47
2.1 リサーチデータ 47
2.1.1 二次データ 48
2.1.2 一次データ 49
2.2 市場予測手法 50
2.2.1 一次エキスパート考察 53
2.3 市場成長率予測 54
2.4 市場の内訳とデータのトライアンギュレーション 56
2.5 調査の前提 57
2.6 リスク分析 57
2.7 リセッション時のインパクト分析 57
3 エグゼクティブサマリー 59
4 更なる考察 63
4.1 ドラッグ・ディスカバリーサービス市場の概要 63
4.2 北米のドラッグディスカバリーサービスの市場：薬剤タイプ別、国別（2022年） 64
4.3 ドラッグディスカバリーサービスの市場シェア、タイプ別（2022年） 64
4.4 ドラッグ・ディスカバリーサービス市場 地域における成長機会 65
5 市場概要 66
5.1 イントロダクション 66
5.2 市場力学 66
5.2.1 促進要因 67
- 5.2.1.1 製薬・バイオテクノロジー分野の研究開発費の拡大 67
- 5.2.1.2 医薬品研究開発パイプラインの増加、アウトソーシングへの依存度の上昇 68
- 5.2.1.3 希少疾病・オーファンドラッグ研究への取り組み 69
- 5.2.1.4 自社での医薬品開発コストが高い 70
5.2.2 抑制要因 71
- 5.2.2.1 ドラッグディスカバリーや動物の使用に関する規制が厳しい 71
5.2.3 市場機会 72
- 5.2.3.1 技術の進歩と新しい創薬技術 72
- 5.2.3.2 エンドユーザーにおける特殊な検査サービスに対する需要の高まり 72
- 5.2.3.3 主要生物製剤の特許切れのお知らせ 73
- 5.2.3.4 新興国における高い成長性 74
5.2.4 課題 74
- 5.2.4.1 熟練した人材が不足している 74
5.2.5 市場動向 75
- 5.2.5.1 創薬におけるAIの導入について 75
- 5.2.5.2 アジア新興国へのアウトソーシングの増加 76
- 5.2.5.3 CROの業界再編 77
- 5.2.5.4 統合されたエンドツーエンドの研究開発サービス提供 78
5.3 レンジ/シナリオ 79
5.4 お客様のビジネスに影響を与えるトレンド／ディスラプション 80
5.5 バリューチェーン分析 81
5.6 エコシステム分析 82
5.7 技術分析 84
5.8 価格分析 86
5.8.1 平均販売価格トレンド分析 86
5.9 規制分析 87
5.9.1 規制当局、政府機関、その他組織 87
5.10 ポーターのファイブフォース分析 89
5.10.1 新規参入の脅威 89
5.10.2 代替品の脅威 90
5.10.3 買い手の交渉力 90
5.10.4 サプライヤーの交渉力 90
5.10.5 競合・競争状況の激しさ 90
5.11 主要なカンファレンスイベント 2022年～2023年 91
5.12 主なステークホルダーと購入基準 92
5.12.1 購買プロセスにおける主要ステークホルダー 92
5.12.2 ドラッグディスカバリーサービスの購入基準 92
6 ドラッグ・ディスカバリーサービスの市場、プロセス別 93
6.1 イントロダクション 94
6.2 ターゲット選定 95
6.2.1 市場成長を支える新技術の開発 95
6.3 ターゲットバリデーション 97
6.4 ヒット・トゥ・リードの同定 100
6.4.1 Hit-to-Lead Identificationが最大のマーケットシェアを占める 100
6.5 リードの最適化 103
6.6 候補者バリデーション 105
7 ドラッグ・ディスカバリーサービスの市場、タイプ別 109
7.1 イントロダクション 110
7.2 ケミストリーサービス 110
7.2.1 ケミストリーサービスがサービスタイプ市場を支配 110
7.3 バイオロジーサービス 112
7.3.1 動物使用に関する規制が市場成長を鈍らせる 112
8 ドラッグ・ディスカバリーサービスの市場、薬品タイプ別 116
8.1 イントロダクション 117
8.2 低分子医薬品 117
8.2.1 低分子医薬品が最大の市場シェアを占める 117
8.3 生物製剤 120
9 ドラッグ・ディスカバリーサービスの市場、治療エリア別 124
9.1 イントロダクション 125
9.2 オンコロジー 126
9.3 感染症 129
9.3.1 疫病の発生がドラッグディスカバリーを後押し 129
9.4 循環器系疾患 132
9.5 神経系疾患 135
9.5.1 神経疾患に対する研究開発投資の増加が市場を牽引 135
9.6 免疫学的疾患 138
9.6.1 免疫疾患の治療薬パイプラインが増加し、市場成長を後押し 138
9.7 内分泌・代謝疾患 140
9.7.1 糖尿病人口の増加が市場を押し上げる 140
9.8 呼吸器疾患 143
9.8.1 呼吸器疾患の負担増が成長を支える 143
9.9 消化器系疾患 146
9.10 泌尿器科疾患・ウィメンズヘルス 148
9.10.1 女性における慢性疾患の増加が市場を押し上げる 148
9.11 その他治療エリア 151
10 ドラッグ・ディスカバリーサービスの市場、エンドユーザー別 155
10.1 イントロダクション 156
10.2 製薬会社・バイオテクノロジー企業 156
10.3 学術機関 166
10.4 その他のエンドユーザー 168
11 ドラッグ・ディスカバリーサービスの市場、地域別 172
11.1 イントロダクション 173
11.2 北米 174
11.2.1 米国 178
- 11.2.1.1 北米市場を制するのはアメリカ 178
11.2.2 カナダ 182
11.2.3 北米：リセッション時のインパクト 185
11.3 ヨーロッパ 186
11.3.1 ドイツ 189
- 11.3.1.1 ドイツが欧州市場で最大のシェアを占める 189
11.3.2 英国 192
- 11.3.2.1 官民協働で市場を盛り上げる 192
11.3.3 フランス 195
- 11.3.3.1 オンコロジー研究プロジェクトの増加が市場を促進 195
11.3.4 イタリア 198
11.3.5 スペイン 201
11.3.6 その他ヨーロッパ 204
11.3.7 ヨーロッパ：リセッション時のインパクト 208
11.4 アジア太平洋 209
11.4.1 中国 214
11.4.2 日本 217
- 11.4.2.1 市場成長を支える医薬品イノベーションに対する政府の取り組み 217
11.4.3 インド 220
11.4.4 オーストラリア 223
11.4.5 韓国 226
11.4.6 その他アジア太平洋 229
11.4.7 アジア太平洋：リセッション時のインパクト 232
11.5 ラテンアメリカ 233
11.5.1 ブラジル 236
- 11.5.1.1 ラテンアメリカ市場を支配するブラジル 236
11.5.2 その他ラテンアメリカ 239
11.5.3 ラテンアメリカ：リセッション時のインパクト 242
11.6 中東・アフリカ 242
11.6.1 成長する医薬品産業が市場を押し上げる 242
11.6.2 中東・アフリカ：リセッション時のインパクト 245
12 競合情勢 246
12.1 概要 246
12.2 主要プレーヤーの主な戦略 247
12.3 市場シェア分析 248
12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 249
12.5 企業評価４象限分類 250
12.5.1 STARS 250
12.5.2 EMERGING LEADERS 250
12.5.3 PERVASIVE PLAYERS 250
12.5.4 PARTICIPANTS 250
12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 252
12.6.1 PROGRESSIVE COMPANIES 252
12.6.2 STARTING BLOCKS 252
12.6.3 RESPONSIVE COMPANIES 252
12.6.4 DYNAMIC COMPANIES 252
12.7 COMPANY FOOTPRINT ANALYSIS 254
12.7.1 企業サービスフットプリント 254
12.7.2 企業地域的なフットプリント 255
12.8 競合シナリオ 256
13 企業プロファイル 259
13.1 主要企業 259
13.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS 259
13.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 263
13.1.3 WUXI APPTEC 270
13.1.4 THERMO FISHER SCIENTIFIC 275
13.1.5 PHARMARON BEIJING CO., LTD. 279
13.1.6 EVOTEC SE 285
13.1.7 EUROFINS SCIENTIFIC SE 293
13.1.8 PIRAMAL ENTERPRISES LIMITED 300
13.1.9 SYNGENE INTERNATIONAL LIMITED 303
13.1.10 CURIA GLOBAL INC. 307
13.1.11 GENSCRIPT BIOTECH CORPORATION 310
13.1.12 JUBILANT PHARMOVA LIMITED 313
13.1.13 FRONTAGE HOLDINGS CORPORATION 317
13.1.14 SHANGHAI MEDICILON INC. 321
13.1.15 AURIGENE DISCOVERY TECHNOLOGIES (DR. REDDY’S LABORATORIES) 323
13.1.16 SYGNATURE DISCOVERY LTD. 326
13.1.17 ONCODESIGN SERVICES 330
13.2 その他企業 333
13.2.1 SELVITA S.A. 333
13.2.2 VIVA BIOTECH HOLDINGS 334
13.2.3 TCG LIFESCIENCES PVT LTD. 335
13.2.4 SHANGHAI CHEMPARTNER CO., LTD. 335
13.2.5 DOMAINEX LTD. 336
13.2.6 NUVISAN PHARMA HOLDING GMBH 337
13.2.7 DALTON PHARMA SERVICES 338
13.2.8 ARAGEN LIFE SCIENCES PVT. LTD. 339
13.2.9 PROMEGA CORPORATION 339
14 付録 340
14.1 ディスカッションガイド 340
14.2 ナレッジストア : MarketAndMarketのサブスクリプションポータル 344
14.3 カスタマイズオプション 346
14.4 関連レポート 346
14.5 執筆者の詳細 347
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
Table of Contents
1 INTRODUCTION 43
1.1 STUDY OBJECTIVES 43
1.2 MARKET DEFINITION 43
1.2.1 INCLUSIONS AND EXCLUSIONS 43
1.3 MARKET SCOPE 44
1.3.1 MARKETS COVERED 44
1.4 YEARS CONSIDERED 44
1.5 CURRENCY CONSIDERED 45
1.6 LIMITATIONS 45
1.7 STAKEHOLDERS 45
1.8 SUMMARY OF CHANGES 46
1.8.1 RECESSION IMPACT 46
2 RESEARCH METHODOLOGY 47
2.1 RESEARCH DATA 47
2.1.1 SECONDARY DATA 48
2.1.2 PRIMARY DATA 49
2.2 MARKET ESTIMATION METHODOLOGY 50
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 53
2.3 MARKET GROWTH RATE PROJECTIONS 54
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 56
2.5 RESEARCH ASSUMPTIONS 57
2.6 RISK ANALYSIS 57
2.7 RECESSION IMPACT ANALYSIS 57
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 63
4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW 63
4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE AND COUNTRY (2022) 64
4.3 DRUG DISCOVERY SERVICES MARKET SHARE, BY TYPE (2022) 64
4.4 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 65
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 66
5.2.1 DRIVERS 67
- 5.2.1.1 Growing R&D expenditure in pharma-biotech sector 67
- 5.2.1.2 Increasing drug R&D pipeline and rising reliance on outsourcing 68
- 5.2.1.3 Initiatives for research on rare diseases and orphan drugs 69
- 5.2.1.4 High cost of in-house drug development 70
5.2.2 RESTRAINTS 71
- 5.2.2.1 Stringent regulations governing drug discovery and animal usage 71
5.2.3 OPPORTUNITIES 72
- 5.2.3.1 Technological advancements and new drug discovery techniques 72
- 5.2.3.2 Rising demand for specialized testing services among end users 72
- 5.2.3.3 Patent expiries of key biologics 73
- 5.2.3.4 High growth prospects in emerging markets 74
5.2.4 CHALLENGES 74
- 5.2.4.1 Shortage of skilled personnel 74
5.2.5 MARKET TRENDS 75
- 5.2.5.1 Adoption of AI in drug discovery 75
- 5.2.5.2 Increased outsourcing to emerging Asian economies 76
- 5.2.5.3 CRO industry consolidation 77
- 5.2.5.4 Integrated end-to-end R&D service offerings 78
5.3 RANGES/SCENARIOS 79
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 80
5.5 VALUE CHAIN ANALYSIS 81
5.6 ECOSYSTEM ANALYSIS 82
5.7 TECHNOLOGY ANALYSIS 84
5.8 PRICING ANALYSIS 86
5.8.1 AVERAGE SELLING PRICE TREND ANALYSIS 86
5.9 REGULATORY ANALYSIS 87
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
5.10 PORTER’S FIVE FORCES ANALYSIS 89
5.10.1 THREAT OF NEW ENTRANTS 89
5.10.2 THREAT OF SUBSTITUTES 90
5.10.3 BARGAINING POWER OF BUYERS 90
5.10.4 BARGAINING POWER OF SUPPLIERS 90
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 90
5.11 KEY CONFERENCES & EVENTS, 2022-2023 91
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 92
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 92
5.12.2 BUYING CRITERIA FOR DRUG DISCOVERY SERVICES 92
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS 93
6.1 INTRODUCTION 94
6.2 TARGET SELECTION 95
6.2.1 DEVELOPMENT OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH 95
6.3 TARGET VALIDATION 97
6.3.1 EMPHASIS ON TARGET VALIDATION TO AVOID LATE-STAGE FAILURE TO PROMOTE MARKET GROWTH 97
6.4 HIT-TO-LEAD IDENTIFICATION 100
6.4.1 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE 100
6.5 LEAD OPTIMIZATION 103
6.5.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST FOCUS ON LEAD OPTIMIZATION 103
6.6 CANDIDATE VALIDATION 105
6.6.1 POSSIBILITY OF DRUG FAILURE DURING DEVELOPMENT TO DRIVE ADOPTION OF CANDIDATE VALIDATION SERVICES 105
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE 109
7.1 INTRODUCTION 110
7.2 CHEMISTRY SERVICES 110
7.2.1 CHEMISTRY SERVICES TO DOMINATE SERVICE TYPE MARKET 110
7.3 BIOLOGY SERVICES 112
7.3.1 RESTRICTIONS ON ANIMAL USAGE TO SLOW MARKET GROWTH 112
8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE 116
8.1 INTRODUCTION 117
8.2 SMALL-MOLECULE DRUGS 117
8.2.1 SMALL-MOLECULE DRUGS TO HOLD LARGEST MARKET SHARE 117
8.3 BIOLOGICS 120
8.3.1 MARKET GROWTH OF BIOLOGICS & CHALLENGES ASSOCIATED WITH DISCOVERY TO DRIVE ADOPTION OF OUTSOURCING SERVICES 120
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA 124
9.1 INTRODUCTION 125
9.2 ONCOLOGY 126
9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH 126
9.3 INFECTIOUS DISEASES 129
9.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY 129
9.4 CARDIOVASCULAR DISEASES 132
9.4.1 HIGH MORTALITY RATES PROMPTING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS 132
9.5 NEUROLOGICAL DISEASES 135
9.5.1 INCREASING INVESTMENTS IN R&D FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET 135
9.6 IMMUNOLOGICAL DISORDERS 138
9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH 138
9.7 ENDOCRINE & METABOLIC DISORDERS 140
9.7.1 INCREASING DIABETIC POPULATION TO BOOST MARKET 140
9.8 RESPIRATORY DISORDERS 143
9.8.1 RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH 143
9.9 DIGESTIVE SYSTEM DISEASES 146
9.9.1 RISING DISEASE INCIDENCE DUE TO LIFESTYLE AND DIETARY CHANGES TO PROPEL MARKET 146
9.10 GENITOURINARY DISEASES & WOMEN’S HEALTH 148
9.10.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO BOOST MARKET 148
9.11 OTHER THERAPEUTIC AREAS 151
10 DRUG DISCOVERY SERVICES MARKET, BY END USER 155
10.1 INTRODUCTION 156
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 156
10.2.1 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE 159
10.2.2 TIER 1 COMPANIES 159
- 10.2.2.1 High investing capacity to drive growth 159
10.2.3 TIER 2 COMPANIES 162
- 10.2.3.1 Limited investment capacity to slow market growth 162
10.2.4 TIER 3 COMPANIES 164
- 10.2.4.1 Insufficient technical advantages to restrain growth 164
10.3 ACADEMIC INSTITUTES 166
10.3.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT 166
10.4 OTHER END USERS 168
11 DRUG DISCOVERY SERVICES MARKET, BY REGION 172
11.1 INTRODUCTION 173
11.2 NORTH AMERICA 174
11.2.1 US 178
- 11.2.1.1 US to dominate North American market 178
11.2.2 CANADA 182
- 11.2.2.1 Growing preference to conduct clinical trials in Canada to support market growth 182
11.2.3 NORTH AMERICA: RECESSION IMPACT 185
11.3 EUROPE 186
11.3.1 GERMANY 189
- 11.3.1.1 Germany to hold largest share of European market 189
11.3.2 UK 192
- 11.3.2.1 Government-private sector collaborations to boost market 192
11.3.3 FRANCE 195
- 11.3.3.1 Growing number of oncology research projects to propel market 195
11.3.4 ITALY 198
- 11.3.4.1 High number of clinical trials and low drug approval time to augment market 198
11.3.5 SPAIN 201
- 11.3.5.1 Short study start-up times and rising R&D expenditure to augment market 201
11.3.6 REST OF EUROPE 204
11.3.7 EUROPE: RECESSION IMPACT 208
11.4 ASIA PACIFIC 209
11.4.1 CHINA 214
- 11.4.1.1 Robust pharma industry and presence of key CROs to account for China’s large market share 214
11.4.2 JAPAN 217
- 11.4.2.1 Government initiatives for drug innovation to support market growth 217
11.4.3 INDIA 220
- 11.4.3.1 Low-cost services, availability of skilled workforce, and strong government support to propel market 220
11.4.4 AUSTRALIA 223
- 11.4.4.1 Large number of clinical trials to make Australia a favorable location for drug discovery 223
11.4.5 SOUTH KOREA 226
- 11.4.5.1 Government initiatives and growing R&D activities for drug development to drive growth 226
11.4.6 REST OF ASIA PACIFIC 229
11.4.7 ASIA PACIFIC: RECESSION IMPACT 232
11.5 LATIN AMERICA 233
11.5.1 BRAZIL 236
- 11.5.1.1 Brazil to dominate Latin American market 236
11.5.2 REST OF LATIN AMERICA 239
11.5.3 LATIN AMERICA: RECESSION IMPACT 242
11.6 MIDDLE EAST & AFRICA 242
11.6.1 GROWING PHARMACEUTICAL INDUSTRY TO BOOST MARKET 242
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 245
12 COMPETITIVE LANDSCAPE 246
12.1 OVERVIEW 246
12.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS 247
12.3 MARKET SHARE ANALYSIS 248
12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 249
12.5 COMPANY EVALUATION QUADRANT 250
12.5.1 STARS 250
12.5.2 EMERGING LEADERS 250
12.5.3 PERVASIVE PLAYERS 250
12.5.4 PARTICIPANTS 250
12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 252
12.6.1 PROGRESSIVE COMPANIES 252
12.6.2 STARTING BLOCKS 252
12.6.3 RESPONSIVE COMPANIES 252
12.6.4 DYNAMIC COMPANIES 252
12.7 COMPANY FOOTPRINT ANALYSIS 254
12.7.1 COMPANY SERVICE FOOTPRINT 254
12.7.2 COMPANY GEOGRAPHIC FOOTPRINT 255
12.8 COMPETITIVE SCENARIO 256
13 COMPANY PROFILES 259
13.1 KEY PLAYERS 259
13.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS 259
13.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 263
13.1.3 WUXI APPTEC 270
13.1.4 THERMO FISHER SCIENTIFIC 275
13.1.5 PHARMARON BEIJING CO., LTD. 279
13.1.6 EVOTEC SE 285
13.1.7 EUROFINS SCIENTIFIC SE 293
13.1.8 PIRAMAL ENTERPRISES LIMITED 300
13.1.9 SYNGENE INTERNATIONAL LIMITED 303
13.1.10 CURIA GLOBAL INC. 307
13.1.11 GENSCRIPT BIOTECH CORPORATION 310
13.1.12 JUBILANT PHARMOVA LIMITED 313
13.1.13 FRONTAGE HOLDINGS CORPORATION 317
13.1.14 SHANGHAI MEDICILON INC. 321
13.1.15 AURIGENE DISCOVERY TECHNOLOGIES (DR. REDDY’S LABORATORIES) 323
13.1.16 SYGNATURE DISCOVERY LTD. 326
13.1.17 ONCODESIGN SERVICES 330
13.2 OTHER COMPANIES 333
13.2.1 SELVITA S.A. 333
13.2.2 VIVA BIOTECH HOLDINGS 334
13.2.3 TCG LIFESCIENCES PVT LTD. 335
13.2.4 SHANGHAI CHEMPARTNER CO., LTD. 335
13.2.5 DOMAINEX LTD. 336
13.2.6 NUVISAN PHARMA HOLDING GMBH 337
13.2.7 DALTON PHARMA SERVICES 338
13.2.8 ARAGEN LIFE SCIENCES PVT. LTD. 339
13.2.9 PROMEGA CORPORATION 339
14 APPENDIX 340
14.1 DISCUSSION GUIDE 340
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 344
14.3 CUSTOMIZATION OPTIONS 346
14.4 RELATED REPORTS 346
14.5 AUTHOR DETAILS 347
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH) TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION) TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION) TABLE 4 DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS TABLE 5 US: BIOLOGICS GOING OFF-PATENT DURING 2023-2027 TABLE 6 DRUG DISCOVERY SERVICES MARKET: PROMINENT ACQUISITIONS, 2023-2021 TABLE 7 SUPPLY CHAIN ECOSYSTEM TABLE 8 DRUG DISCOVERY AND DEVELOPMENT PROCESS & COST OVERVIEW (2018 VS 2022) TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 13 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS TABLE 14 DRUG DISCOVERY SERVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS TABLE 15 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 16 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2021-2028 (USD MILLION) TABLE 17 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 18 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 19 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 20 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 21 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2021-2028 (USD MILLION) TABLE 22 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 23 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 24 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 25 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 26 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2021-2028 (USD MILLION) TABLE 27 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 28 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 29 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 30 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 31 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2021-2028 (USD MILLION) TABLE 32 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 33 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 34 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 35 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 36 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2021-2028 (USD MILLION) TABLE 37 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 38 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 39 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 40 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 41 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 42 CHEMISTRY SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION) TABLE 43 NORTH AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 44 EUROPE: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 45 ASIA PACIFIC: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 46 LATIN AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 47 BIOLOGY SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION) TABLE 48 NORTH AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 49 EUROPE: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 50 ASIA PACIFIC: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 51 LATIN AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 52 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 53 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2021-2028 (USD MILLION) TABLE 54 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 55 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 56 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 57 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 58 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2021-2028 (USD MILLION) TABLE 59 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 60 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 61 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 62 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 63 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 64 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2022) TABLE 65 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION) TABLE 66 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 67 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 68 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 69 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 70 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION) TABLE 71 NORTH AMERICA DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 72 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 73 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 74 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 75 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (AS OF DECEMBER 2022) TABLE 76 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021-2028 (USD MILLION) TABLE 77 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 78 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 79 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 80 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 81 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2022) TABLE 82 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2021-2028 (USD MILLION) TABLE 83 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 84 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 85 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 86 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 87 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022) TABLE 88 DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION) TABLE 89 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 90 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 91 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 92 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 93 DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2021-2028 (USD MILLION) TABLE 94 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 95 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 96 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 97 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 98 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS (2022) TABLE 99 DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2021-2028 (USD MILLION) TABLE 100 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 101 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 102 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 103 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 104 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2021-2028 (USD MILLION ) TABLE 105 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 106 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 107 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 108 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 109 DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2021-2028 (USD MILLION) TABLE 110 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 111 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 112 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 113 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 114 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021-2028 (USD MILLION) TABLE 115 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 116 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 117 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 118 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 119 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 120 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) TABLE 121 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 122 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 123 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 124 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 125 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 126 TOP PHARMA COMPANIES, BY REVENUE (2022) TABLE 127 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2021-2028 (USD MILLION) TABLE 128 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 129 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 130 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 131 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 132 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2021-2028 (USD MILLION) TABLE 133 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 134 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 135 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 136 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 137 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2021-2028 (USD MILLION) TABLE 138 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 139 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 140 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 141 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 142 DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021-2028 (USD MILLION) TABLE 143 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 144 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 145 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 146 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 147 DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION) TABLE 148 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 149 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 150 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 151 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 152 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION) TABLE 153 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 154 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 155 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 156 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 157 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 158 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 159 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 160 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 161 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 162 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 163 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 164 US: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 165 US: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 166 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 167 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 168 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 169 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 170 CANADA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 171 CANADA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 172 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 173 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 174 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 175 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 176 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 177 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 178 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 179 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 180 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 181 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 182 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 183 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 184 GERMANY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 185 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 186 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 187 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 188 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 189 UK: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 190 UK: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 191 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 192 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 193 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 194 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 195 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 196 FRANCE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 197 NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022) TABLE 198 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 199 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 200 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 201 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 202 ITALY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 203 ITALY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 204 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 205 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 206 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 207 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 208 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 209 SPAIN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 210 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 211 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 212 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 213 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 214 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 215 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 216 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 217 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 218 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 219 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 220 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 221 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 222 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 223 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 224 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 225 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 226 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 227 CHINA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 228 CHINA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 229 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2020 VS. 2022 TABLE 230 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 231 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 232 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 233 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 234 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 235 JAPAN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 236 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 237 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 238 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 239 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 240 INDIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 241 INDIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 242 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 243 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 244 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 245 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 246 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 247 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 248 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 249 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 250 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 251 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 252 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 253 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 254 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 255 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 256 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 257 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 258 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 259 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 260 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 261 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 262 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 263 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 264 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 265 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 266 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 267 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 268 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 269 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 270 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 271 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 272 BRAZIL: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 273 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 274 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 275 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 276 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 277 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 278 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 279 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 280 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION) TABLE 281 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION) TABLE 282 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 283 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 284 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021-2028 (USD MILLION) TABLE 285 DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION TABLE 286 SERVICE PORTFOLIO ANALYSIS: DRUG DISCOVERY SERVICES MARKET (2022) TABLE 287 GEOGRAPHIC REVENUE MIX: DRUG DISCOVERY SERVICES MARKET (2022) TABLE 288 DRUG DISCOVERY SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2020-MARCH 2023 TABLE 289 DRUG DISCOVERY SERVICES MARKET: DEALS, JANUARY 2020-MARCH 2023 TABLE 290 DRUG DISCOVERY SERVICES MARKET: EXPANSION: JANUARY 2020-MARCH 2023 TABLE 291 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW TABLE 292 CHARLES RIVER LABORATORIES INTERNATIONAL: BUSINESS OVERVIEW TABLE 293 WUXI APPTEC: BUSINESS OVERVIEW TABLE 294 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW TABLE 295 PHARMARON BEIJING CO., LTD.: BUSINESS OVERVIEW TABLE 296 EVOTEC SE: BUSINESS OVERVIEW TABLE 297 EUROFINS SCIENTIFIC SE: BUSINESS OVERVIEW TABLE 298 PIRAMAL ENTERPRISES LIMITED: BUSINESS OVERVIEW TABLE 299 SYNGENE INTERNATIONAL LIMITED: BUSINESS OVERVIEW TABLE 300 CURIA GLOBAL INC.: BUSINESS OVERVIEW TABLE 301 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW TABLE 302 JUBILANT PHARMOVA LIMITED: BUSINESS OVERVIEW TABLE 303 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW TABLE 304 SHANGHAI MEDICILON INC.: BUSINESS OVERVIEW TABLE 305 DR. REDDY’S LABORATORIES LTD.: BUSINESS OVERVIEW TABLE 306 SYGNATURE DISCOVERY LTD: BUSINESS OVERVIEW TABLE 307 ONCODESIGN SERVICES: BUSINESS OVERVIEW
FIGURE 1 RESEARCH DESIGN FIGURE 2 DRUG DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES FIGURE 3 DRUG DISCOVERY SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022 FIGURE 5 ILLUSTRATIVE EXAMPLE OF COMPANY REVENUE ANALYSIS, 2022 FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES FIGURE 7 DRUG DISCOVERY SERVICES MARKET (SUPPLY-SIDE): CAGR PROJECTIONS FIGURE 8 DRUG DISCOVERY SERVICES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS FIGURE 9 DATA TRIANGULATION METHODOLOGY FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) FIGURE 11 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION) FIGURE 12 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) FIGURE 13 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) FIGURE 14 GEOGRAPHICAL SNAPSHOT OF DRUG DISCOVERY SERVICES MARKET, 2022 FIGURE 15 INCREASING R&D EXPENDITURE IN PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH FIGURE 16 SMALL-MOLECULE DRUGS HELD LARGEST SHARE OF NORTH AMERICAN DRUG DISCOVERY MARKET IN 2022 FIGURE 17 CHEMISTRY SERVICES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 FIGURE 18 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023-2028 FIGURE 19 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FIGURE 20 RISING GLOBAL PHARMACEUTICAL R&D SPENDING, 2014-2028 FIGURE 21 ACTIVE PHARMACEUTICAL PIPELINE, 2012-2022 FIGURE 22 NUMBER OF DRUGS GIVEN ORPHAN DRUG STATUS (2013-2021) FIGURE 23 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010-2020 (USD BILLION) FIGURE 24 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON DRUG DISCOVERY SERVICES MARKET GROWTH FIGURE 25 REVENUE SHIFT AND NEW POCKETS FOR DRUG DISCOVERY SERVICE PROVIDERS FIGURE 26 VALUE CHAIN ANALYSIS OF DRUG DISCOVERY SERVICES MARKET: HIT-TO-LEAD IDENTIFICATION AND LEAD OPTIMIZATION PHASES ADD MAXIMUM VALUE FIGURE 27 ECOSYSTEM ANALYSIS: DRUG DISCOVERY SERVICES MARKET FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DRUG DISCOVERY SERVICES FIGURE 29 KEY BUYING CRITERIA FOR END USERS FIGURE 30 NUMBER OF ONCOLOGY CLINICAL TRIALS, 2012-2022 (THOUSAND) FIGURE 31 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000-2045 (MILLION) FIGURE 32 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2011-2021 FIGURE 33 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2022) FIGURE 34 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022) FIGURE 35 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2022) FIGURE 36 KEY STRATEGIES ADOPTED BY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2020-2023 FIGURE 37 DRUG DISCOVERY SERVICES MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022 FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS, 2020-2022 FIGURE 39 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION QUADRANT, 2022 FIGURE 40 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022 FIGURE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022) FIGURE 42 CHARLES RIVER LABORATORIES INTERNATIONAL: COMPANY SNAPSHOT (2022) FIGURE 43 WUXI APPTEC: COMPANY SNAPSHOT (2021) FIGURE 44 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2022) FIGURE 45 PHARMARON BEIJING CO., LTD.: COMPANY SNAPSHOT (2021) FIGURE 46 EVOTEC SE: COMPANY SNAPSHOT (2021) FIGURE 47 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2022) FIGURE 48 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2021) FIGURE 49 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2021) FIGURE 50 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021) FIGURE 51 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2021) FIGURE 52 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021) FIGURE 53 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2021) FIGURE 54 ONCODESIGN SERVICES: COMPANY SNAPSHOT (2021)
